{"groups":[{"description":"Participants received Abemaciclib orally at 150 milligrams (mg) twice daily with at least 6 hours between doses for up to 2 years or until evidence of disease recurrence or other discontinuation criteria were met, whichever occurs first. Endocrine therapy (physicians' choice) standard-of-care was administered according to package label until discontinuation criteria were met.","id":"FG000","title":"150 mg Abemaciclib + Endocrine Therapy"},{"description":"Endocrine therapy (physicians' choice) standard-of-care was administered according to package label until discontinuation criteria were met.","id":"FG001","title":"Endocrine Therapy"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"119"},{"groupId":"FG001","numSubjects":"134"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"13"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Missing disposition data"},{"reasons":[{"groupId":"FG000","numSubjects":"2027"},{"groupId":"FG001","numSubjects":"2074"}],"type":"On study treatment"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"2808"},{"groupId":"FG001","numSubjects":"2829"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"2791"},{"groupId":"FG001","numSubjects":"2800"}],"type":"Received at Least One Dose of Study Drug"},{"achievements":[{"groupId":"FG000","numSubjects":"650"},{"groupId":"FG001","numSubjects":"607"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"2158"},{"groupId":"FG001","numSubjects":"2222"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Completers included participants who had recurrence disease, death due to any cause, and participants off treatment but on study follow-up."}